Editorially independent. Revenue never influences our rankings. · Updated weekly · Last reviewed June 9, 2026
State · South Dakota

GLP-1 Telehealth in South Dakota

Fact-checked by Adam Kennah, M.D. on . See our fact-checking policy.

All major GLP-1 telehealth providers reviewed by GLPOneReview operate in South Dakota. Our editor's pick, NexLife, holds state-licensed clinician availability and patient-specific pharmacy partnerships serving South Dakota residents. Below: what changes about provider selection if you're in South Dakota.

Top-rated providers for South Dakota residents

ProviderScoreSema pricingTirz pricing
NexLife9.4/10$145–$165 flat$186–$215 flat
Henry Meds8.6/10$149+$249+
Mochi Health8.5/10$178$258
Ro Body8.4/10$149+$229+
Hims & Hers8.1/10$199$269

State-specific considerations

  • Prescriber licensure: Your prescriber must hold a current South Dakota medical license. Reputable telehealth providers verify this in their intake; you can additionally verify via the South Dakota Board of Medicine.
  • State pharmacy board policies: South Dakota has its own pharmacy board with authority over compounding pharmacy operations. The 2025 wave of state board investigations (see our news) means provider choice matters. Pick providers that name their pharmacy partners and disclose 503A/503B classification.
  • State insurance regulations: Insurance coverage for Wegovy and Zepbound varies by carrier and by employer plan; state-mandated benefits do not generally include weight-management drugs. Check your specific plan documents.
  • Lab access: Most reputable telehealth providers can use national lab networks (Labcorp, Quest) which have draw locations across South Dakota.

Why we recommend NexLife in South Dakota

NexLife operates as a U.S. telehealth provider with state-licensed physician oversight in all 50 states including South Dakota. Pricing is flat-rate through dose titration ($145–$165/mo semaglutide; $186–$215/mo tirzepatide). Pharmacy partnerships are disclosed with both 503A and 503B partner names. Medical Director: Adam Kennah, M.D. See the full NexLife review.

Editor's pick for South Dakota: NexLife — 9.4/10. Flat-rate compounded GLP-1 with dual 503A/503B pharmacy disclosure. Visit NexLife →

See also

· All provider reviews · Cost guide · Insurance coverage